ClinicalTrials.gg
RecruitingNCT07100106MoonROSEUpdated Oct 26, 2026

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

A Phase 1/2 interventional study of GDC-4198 and Giredestrant in Breast Cancer, sponsored by Genentech, Inc.. Recruiting at 77 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 26, 2026Eligibility revised14 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 229 studies in Breast Neoplasms by Hoffmann-La Roche — 16 open to participants now, 28 under way, 13 of them phase 3. Breast Neoplasms · Hoffmann-La Roche.

Planned enrollment
57th of 170
285 · median 151
Started
2025
with 2 others
Phase 1/2
11 of 229
2 open now
Primary completion
2028-08
later than 15 of 27 live
Registered
218th of 229
by date

Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 57th largest by planned enrollment of the 170 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 15 of the 27 other live ones, and was the 218th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 229 studies in Breast Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Breast Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Phase Ib and Phase II. Phase Ib will evaluate the safety and pharmacokinetics (PK) of GDC-4198 alone and in combination with giredestrant. Phase II stage will compare the activity and safety of GDC-4198 and giredestrant with abemaciclib and giredestrant.

Participants from Study RGT-419B_01-101 (NCT05304962) who are experiencing clinical benefit with GDC-4198, as determined by the investigator, may enroll in this study and continue receiving GDC-4198 at their current dose level following closure of Study RGT-419B_01-101.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed adenocarcinoma of the breast that is locally advanced or .
  • Previously documented ER+ and - tumor according to American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) or European Society of Medical Oncology (ESMO) guidelines or any national guidelines with criteria conforming to ASCO/CAP or ESMO guidelines.
  • Disease progression during or after treatment with an approved cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and approved endocrine therapy (ET) in the locally advanced or metastatic setting.
  • Measurable or non-measurable evaluable, disease per version 1.1 (RECIST v1.1).
  • (ECOG) Performance Status of 0 or 1.
  • >= 6 months.
  • Current participant enrolled in Study RGT-419B_01-101 who is experiencing clinical benefit from GDC-4198, as determined by the investigator, at the time of consent and enrollment in this study.

Exclusion criteria

Exclusion Criteria:

  • Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term appropriate for treatment with cytotoxic chemotherapy at time of entry into the study, as per national or local treatment guidelines.
  • Have received more than one- for locally advanced or disease.
  • Have received prior chemotherapy for metastatic breast cancer.
  • Treatment with an approved oral ET within 7 days prior to initiation of study drug; treatment with fulvestrant or an approved CDK4/6 inhibitor within 21 days prior to initiation of study drug.
  • Malabsorption condition or other gastrointestinal (GI) conditions/surgeries that the investigator assesses may significantly interfere with enteral absorption
  • History of within 3 years prior to screening, except for cancer under investigation in this study and malignancies with a negligible risk of metastasis or death.
  • Known allergy or to any component of the study treatments.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Phase Ib: Dose-Finding Stage

    Participants will receive GDC-4198 as monotherapy and in combination with giredestrant, 30 milligrams (mg), orally, daily, as per a pre-defined dosing regimen during each cycle until unacceptable toxicity or disease progression and/or loss of clinical benefit. (1 cycle=28 days). Participants from study RGT-419B\_01-101 will continue receiving GDC-4198 at their current dose level following closure of study RGT-419B\_01-101.

    Drug: GDC-4198 · Drug: Giredestrant

  • Experimental
    Phase II: Arm A

    Participants will receive GDC-4198, higher dose, in combination with giredestrant, 30 mg, orally, daily, as per a pre-defined dosing regimen during each cycle until unacceptable toxicity or disease progression and/or loss of clinical benefit. (1 cycle=28 days).

    Drug: GDC-4198 · Drug: Giredestrant

  • Experimental
    Phase II: Arm B

    Participants will receive GDC-4198, lower dose, in combination with giredestrant, 30 mg, orally, daily, as per a pre-defined dosing regimen during each cycle until unacceptable toxicity or disease progression and/or loss of clinical benefit. (1 cycle=28 days).

    Drug: GDC-4198 · Drug: Giredestrant

  • Experimental
    Phase II: Arm C

    Participants will receive abemaciclib, 150 mg twice daily, in combination with giredestrant, 30 mg, orally, daily, as per a pre-defined dosing regimen during each cycle until unacceptable toxicity or disease progression and/or loss of clinical benefit. (1 cycle=28 days).

    Drug: Giredestrant · Drug: Abemaciclib

Interventions

  • GDC-4198 will be administered orally.

    Also known as: RGT-419B, RO7840734

  • Giredestrant will be administered orally.

    Also known as: GDC-9545, RO7197597

  • Abemaciclib will be administered orally.

06

What researchers measure

Primary outcomes

  1. Phase Ib: Incidence and Severity of Adverse Events (AEs)

    Severity of AEs determined according to the CTCAE v5.0 grading scale

    Time frame: Up to 36 months

  2. Phase Ib: Number of Participants With Dose-Limiting Toxicity (DLTs)

    Time frame: From Day 1 to Day 28 of Cycle 1 (1 cycle=28 days)

  3. Phase II: Progression-free Survival (PFS)

    Time frame: Up to 36 months

Secondary outcomes

  1. Phase Ib: Objective Response Rate (ORR)

    Time frame: Up to 36 months

  2. Phase Ib: Clinical Benefit Rate (CBR)

    Time frame: Up to 36 months

  3. Phase II: ORR

    Time frame: Up to 36 months

  4. Phase II: Duration of Response (DOR)

    Time frame: Up to 36 months

  5. Phase II: CBR

    Time frame: Up to 36 months

  6. Phase II: Overall Survival (OS)

    Time frame: Up to 36 months

  7. Phase II: OS Rate at 6 Months and 12 Months

    Time frame: Month 6, Month 12

  8. Phase II: PFS Rate at 6 Months and 12 Months

    Time frame: Month 6, Month 12

  9. Phase II: Incidence and Severity of Adverse Events (AEs)

    Severity of AEs determined according to the CTCAE v5.0 grading scale

    Time frame: Up to 36 months

  10. Phase II: Plasma Concentration of GDC-4198

    Time frame: Up to 36 months

  11. Phase II: Recommended Dose of GDC-4198

    Time frame: Up to 36 months

07

Study locations

77 of 77 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 34 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 3, 2025
StartActual
Oct 7, 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 1 site removed
Show 14 added (5 United States, 3 Germany, 2 Italy, 1 Brazil, 1 China, 1 Canada, 1 Spain)
  • Clearview Cancer Institute - Huntsville · Huntsville, United States
  • University of Colorado Cancer Center · Aurora, United States
  • Cleveland Clinic Mercy Hospital · Canton, United States
  • Cleveland Clinic Taussig Cancer Center · Cleveland, United States
  • Beneficencia Portuguesa de Sao Paulo · São Paulo, Brazil
  • Fujian Cancer Hospital · Fuzhou, China
  • Medizinische Hochschule Hannover · Hanover, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden · Dresden, Germany
  • Uniklinikum Heidelberg · Heidelberg, Germany
  • Asst Papa Giovanni XXIII · Bergamo, Italy
  • Tennesse Oncology - Mt. Juliet Clinic · Mount Juliet, United States
  • BC Cancer Vancouver Centre · Vancouver, Canada
  • Azienda Ospedaliero Universitaria Di Bologna_Policlinico S Orsola Malpighi-Via Albertoni · Bologna, Italy
  • ICO l?Hospitalet ? Hospital Duran i Reynals · L'Hospitalet de Llobregat, Spain
Show 1 removed
  • IRCCS Azienda Ospedaliero Universitaria di Bologna · Bologna, Italy
across 2 updates, Oct 6, 2026 – Oct 26, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedCurrent participant enrolled in Study RGT-419B_01-101 who is experiencing clinical benefit from GDC-4198, as determined by the investigator, at the time of consent and enrollment in this study.
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    4 sites added, 1 site removed
    Show 4 added (1 United States, 1 Canada, 1 Italy, 1 Spain)
    • Tennesse Oncology - Mt. Juliet Clinic · Mount Juliet, United States
    • BC Cancer Vancouver Centre · Vancouver, Canada
    • Azienda Ospedaliero Universitaria Di Bologna_Policlinico S Orsola Malpighi-Via Albertoni · Bologna, Italy
    • ICO l?Hospitalet ? Hospital Duran i Reynals · L'Hospitalet de Llobregat, Spain
    Show 1 removed
    • IRCCS Azienda Ospedaliero Universitaria di Bologna · Bologna, Italy
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedCurrent participant enrolled in Study RGT-419B_01-101 who is experiencing clinical benefit from GDC-4198, as determined by the investigator, at the time of consent and enrollment in this study.
    + 2 other changes: description and arm descriptions
  2. Oct 6, 2026
    10 sites added
    Show 10 added (4 United States, 3 Germany, 1 Brazil, 1 China, 1 Italy)
    • Clearview Cancer Institute - Huntsville · Huntsville, United States
    • University of Colorado Cancer Center · Aurora, United States
    • Cleveland Clinic Mercy Hospital · Canton, United States
    • Cleveland Clinic Taussig Cancer Center · Cleveland, United States
    • Beneficencia Portuguesa de Sao Paulo · São Paulo, Brazil
    • Fujian Cancer Hospital · Fuzhou, China
    • Medizinische Hochschule Hannover · Hanover, Germany
    • Universitaetsklinikum Carl Gustav Carus an der TU Dresden · Dresden, Germany
    • Uniklinikum Heidelberg · Heidelberg, Germany
    • Asst Papa Giovanni XXIII · Bergamo, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07100106
Lead sponsor
Genentech, Inc.
Collaborators
Roche (China) Holding Ltd.
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Oct 7, 2025
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Reference Study ID Number: GO46021 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vustanaciclib

Start the discussion